Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients

Kostopoulos, Ioannis V.; Kakalis, Antonis; Birmpilis, Anastasios I.; Angelis, Nikolaos; Orologas-Stavrou, Nikolaos; Rousakis, Pantelis; Panteli, Chrysanthi; Gavriatopoulou, Maria; Kastritis, Efstathios; Dimopoulos, Meletios Α.; Tsitsilonis, Ourania E.; Terpos, Evangelos

doi:10.1002/ajh.26823

Cited by 6 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GSK2857916 is an FDA-approved agent available for MM, which has been found to activate the PERK and increase phosphorylation of elF2 α to induce ER stress, exposing CRT, HSP70, HSP90, and IL8 with increased ATP and HMGB1 to trigger ICD in NCI-H929 cells, improving MM therapy in vitro and in vivo 436 . Similarly, belantamab mafodotin, a recent FDA-approved agent available for MM, has been found to increase CRT and HMGB1 to trigger ICD, improving MM therapy 437 . Imiquimod, an FDA-approved agent available for skin malignancies and viral warts, has been reported to produce ROS and activate the PERK/elF2 α axis to induce ER stress, leading to the release of CRT, ATP, and HMGB1 to trigger ICD in B16F10 cells, and slowing tumor growth in the B16F10 syngeneic model 438 .…”

Section: Targeting Non-apoptotic Rcd Subroutines With Small-molecule ...mentioning

confidence: 99%

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Jin,

Tong

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Targeting Non-apoptotic Rcd Subroutines With Small-molecule ...mentioning

confidence: 99%

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Jin,

Tong

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…The production of ROS not only facilitates the direct eradication of tumor cells but also enhances the release of antigens, including calreticulin (CRT), heat shock proteins (HSPs), adenosine triphosphate (ATP), and high-mobility group box 1 (HMGB1). These antigens are then recognized by the immune system, further stimulating an immune reaction against the tumor [54][55][56][57].…”

Section: Photodynamic Therapymentioning

confidence: 99%

Advances in Nanodynamic Therapy for Cancer Treatment

Zhang,

Huang,

Huang

2024

Nanomaterials

View full text Add to dashboard Cite

Nanodynamic therapy (NDT) exerts its anti-tumor effect by activating nanosensitizers to generate large amounts of reactive oxygen species (ROS) in tumor cells. NDT enhances tumor-specific targeting and selectivity by leveraging the tumor microenvironment (TME) and mechanisms that boost anti-tumor immune responses. It also minimizes damage to surrounding healthy tissues and enhances cytotoxicity in tumor cells, showing promise in cancer treatment, with significant potential. This review covers the research progress in five major nanodynamic therapies: photodynamic therapy (PDT), electrodynamic therapy (EDT), sonodynamic therapy (SDT), radiodynamic therapy (RDT), and chemodynamic therapy (CDT), emphasizing the significant role of advanced nanotechnology in the development of NDT for anti-tumor purposes. The mechanisms, effects, and challenges faced by these NDTs are discussed, along with their respective solutions for enhancing anti-tumor efficacy, such as pH response, oxygen delivery, and combined immunotherapy. Finally, this review briefly addresses challenges in the clinical translation of NDT.

show abstract

“… 18 DAMPs enhance the immunogenicity of tumor cells, promote the recognition and antigen-presenting ability of DCs to cancer cells, stimulate DCs maturation, and mature DCs activate specific T cells to attack cancer cells. Currently, merely a few clinically relevant drugs have been demonstrated to trigger true ICD, such as adriamycin and onioncyclines, oxaliplatin, 19 lurbinectedin, 20 and belantamab mafodotin, 21 , 22 which have been employed in the treatment of several malignancies. Previous studies demostrated that Oxaliplatin causes ICD in HCC and has a synergistic impact when combined with anti-PD-1 antibodies.…”

Section: Introductionmentioning

confidence: 99%

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma

Peng,

Xu,

2024

JHC

View full text Add to dashboard Cite

Introduction Immunogenic cell death (ICD) can enhance the potency of immunotherapy in cancer treatment. Nevertheless, it is ambiguous how ICD-related genes (ICDRGs) contribute to hepatocellular carcinoma (HCC). Methods Single-cell RNA sequencing (scRNA-seq) data were used to distinguish malignant cells from normal cells in the HCC tumor microenvironment(TME). Bulk RNA sequencing data was employed to acquire the landscape of the 33 ICDRGs. Unsupervised clustering identified two ICD molecular subtypes. The cellular infiltration characteristics and biological behavior in different subtypes were analyzed by ssGSEA. Subsequently, differentially expressed genes (DEGs) between the two subtypes were determined, based on which patients were classified into three gene clusters. Then, the prognostic model was constructed by Lasso-Cox analysis. Finally, we investigated the expression of risk genes in cancer cell line encyclopedia (CCLE) and validated the function of NKX3-2 in vitro experiments. Results ICD scores and ICDRGs expression in malignant cells were significantly lower than in normal cells by scRNA-seq analysis. ICD-high subtype was characterized by ICD-related gene overexpression and high levels of immune infiltration abundance and immune checkpoints; Three DEGs-related gene clusters were likewise strongly linked to stromal and immunological activation. In the ICD-related prognostic model consisting of NKX3-2, CHODL, MMP1, NR0B1, and CTSV, the low-risk group patients had a better endpoint and displayed increased susceptibility to immunotherapy and chemotherapeutic drugs like 5-Fluorouracil, afatinib, bortezomib, cediratinib, lapatinib, dasatinib, gefitinib and crizotinib. Moreover, NKX3-2 amplification in HCC samples has been verified by experiments, and its disruption suppressed the proliferation and invasion of tumor cells. Conclusion Our study highlighted the potential of the ICDRGs risk score as a prognostic indicator to aid in the accurate diagnosis and immunotherapy sensitivity of HCC.

show abstract

Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients

Abstract: Despite the outstanding progress in the clinical management of Multiple Myeloma (MM) over the last decades, the disease remains incurable with unavoidable patients' relapses. In this context, there is

Cited by 6 publications

References 10 publications

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Advances in Nanodynamic Therapy for Cancer Treatment

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma

Contact Info

Product

Resources

About